Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 20/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13324629 | 1.00 | F2R (0.83) | F2R | |
| SCHEMBL12759520 | 0.92 | F2R (0.85) | F2R | |
| SCHEMBL14375452 | 0.91 | F2R (1.00) | F2R | |
| SCHEMBL13513129 | 0.90 | F2R (1.00) | F2R | |
| SCHEMBL13324645 | 0.90 | F2R (1.00) | F2R | |
| SCHEMBL15282339 | 0.90 | F2R (1.00) | F2R | |
| SCHEMBL14203709 | 0.90 | F2R (1.00) | F2R | |
| SCHEMBL11969013 | 0.90 | F2R (1.00) | F2R | |
| SCHEMBL11994829 | 0.90 | F2R (1.00) | F2R | |
| SCHEMBL11969016 | 0.90 | F2R (1.00) | F2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713999-B2 | Thrombin receptor antagonists | SCHERING CORPORATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713999-B2 | Thrombin receptor antagonists | SCHERING CORPORATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-7304078-B2 | Thrombosis; cardiovascular disorders; restenosis; hypotensive agents; antiarrhythmia agents; antiinflamamtroy agents; central nervous system disorders | SCHERING CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304078-B2 | Thrombosis; cardiovascular disorders; restenosis; hypotensive agents; antiarrhythmia agents; antiinflamamtroy agents; central nervous system disorders | SCHERING CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070270439-A1 | THROMBIN RECEPTOR ANTAGONISTS | SCHERING CORPORATION | 2007-11-22 | — | — | US | disclosed |
| US-20070270439-A1 | THROMBIN RECEPTOR ANTAGONISTS | SCHERING CORPORATION | 2007-11-22 | — | — | US | disclosed |
| US-20070179187-A1 | THROMBIN RECEPTOR ANTAGONISTS | SCHERING CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-20070179187-A1 | THROMBIN RECEPTOR ANTAGONISTS | SCHERING CORPORATION | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179187-A1 | THROMBIN RECEPTOR ANTAGONISTS | TBXA2R, BDKRB2, AGTR2 | F2R 7/4885 |
| US-20070270439-A1 | THROMBIN RECEPTOR ANTAGONISTS | TBXA2R, BDKRB2, AGTR2 | F2R 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.